Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Neukoplast™ (NK-92)
Neukoplast · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Neukoplast™ (NK-92) | EXPERIMENTAL | Neukoplast™ will be infused in three doses.1 x 10e9 cells/m2 dose, 3 x 10e9 cells/m2 dose, 5 x 10e9 cells/m2 dose. |
| Name | Type | Description |
|---|---|---|
| Neukoplast™ (NK-92) | BIOLOGICAL | The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion. |
Inclusion Criteria: * Patients with refractory/relapse acute myeloid leukemia. Patients must not have received radiotherapy, chemotherapy (with the exception of hydroxyurea which must be discontinued 72 hours prior to therapy) or biological therapy within the preceding 2 weeks of the planned first ...
Neukoplast is being studied for the treatment of refractory or relapsed acute myeloid leukemia (AML), a cancer of the blood and bone marrow. It is an investigational therapy, not an approved treatment, and has been evaluated in a single Phase 1 clinical trial in adults with AML.
Neukoplast is being developed by ImmunityBio, Inc., a biopharmaceutical company whose common stock trades on the Nasdaq under the ticker symbol IBRX. ImmunityBio is the sponsor of the clinical program evaluating Neukoplast in acute myeloid leukemia.
Neukoplast is in Phase 1 clinical development. It has been evaluated in one completed Phase 1 trial in patients with refractory or relapsed acute myeloid leukemia. It is investigational and has not been approved by the FDA for any indication.
Neukoplast has been studied in the Phase 1 trial NCT00900809, titled QUILT-3.018: Neukoplast (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia. The trial enrolled 7 participants in the United States and is now completed.
Yes, Neukoplast is also known as Neukoplast (NK-92). The NK-92 designation refers to the natural killer cell line from which the therapy is derived. Both names refer to the same investigational product being developed by ImmunityBio for acute myeloid leukemia.